Crestline Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Crestline Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-488,243	Closed	-$1.52M	–	167
2018 Q2	$1.52M	Buy	488,243 +41,541	+9%	+$126K	0.16%	164
2018 Q1	$1.07M	Buy	446,702 +179,590	+67%	+$597K	0.13%	145
2017 Q4	$1.04M	Buy	267,112 +44,093	+20%	+$146K	0.11%	106
2017 Q3	$562K	Buy	+223,019	New	+$612K	0.08%	118

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Crestline Management's CPRX Position: Q3 2018 in Review

Crestline Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2018, closing a stake of 488,243 shares — an estimated $1.52M sold.

Crestline Management first reported a position in CPRX in Q3 2017 and held it in 4 quarters. The position peaked at $1.52M in Q2 2018. 97 funds tracked by Wall St. Rank hold CPRX as of Q3 2018.

Crestline Management reported no remaining Catalyst Pharmaceutical position as of Q3 2018 after selling out during the quarter.
Crestline Management sold 488,243 Catalyst Pharmaceutical shares in Q3 2018, an estimated $1.52M.
Crestline Management first reported a position in Catalyst Pharmaceutical in Q3 2017 and held it in 4 quarters.
Crestline Management's Catalyst Pharmaceutical position peaked at $1.52M in Q2 2018.
97 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.